

MANUFACTURERS OF PARENTERAL PRODUCTS [CIN: L24230GJ1980PLC003843]



ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: <u>denischem401@gmail.com</u>

14th August, 2023

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400001

Company Code No. 537536

Dear Sirs,

Sub: - Outcome of Board Meeting - Submission of Un-audited Financial Results for the Quarter ended on 30th June, 2023

We refer to our letter dated 2nd August, 2023 informing the date of Meeting of the Board of Directors of the Company, please note that the Board of Directors in their meeting held today, have taken on record the Un-audited Financial Results for the quarter ended on 30th June, 2023.

We are enclosing herewith copy of the said Unaudited Financial Results for the quarter ended on 30th June, 2023 along with Limited Review Report thereon.

This is as per Regulation – 33 and other applicable provisions of the SEBI (LODR) Regulations, 2015.

The Meeting of Board of Directors was commenced at 10:00 a.m. and concluded at 1:30 p.m.

Thanking you,

Yours faithfully, for DENIS CHEM LAB LIMITED

HIMANSHU C. PATEL MANAGING DIRECTOR (DIN: 00087114)

Encl: As above.



MANUFACTURERS OF PARENTERAL PRODUCTS [CIN: L24230GJ1980PLC003843]



 ADDRESS:
 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA

 TEL.:
 +91 (79) 26925716, 26925719
 FAX:
 +91 (79) 26925710
 Email: denischem401@gmail.com

STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2023

(Rs. in lakhs)

	Particulars	Q	Previous Year ended on		
		30-06-2023	31-03-2023	30-06-2022	31-03-2023
(Refer Notes Below)		(Un-audited)	(Audited)	(Un-audited)	(Audited)
1	Revenue from operations	4247.92	3972.74	3928.72	16084.89
2	Other income	1.26	33.73	7.52	59.23
3	Total Income (1+2)	4249.18	4006.47	3936.24	16144.12
4	Expenses				
	a. Cost of Materials consumed	2006.56	1857.76	1964.15	7479.04
	b.Purchases of stock-in-trade	187.54	191.87	240.68	861.65
	c. Changes in inventories of finished goods, work-in-progress and stock-in- trade	(108.89)	4.84	80.12	105.27
	d.Employee benefits expense	301.85	333.95	282.94	1302.62
	e. Finance costs	8.81	26.18	17.24	64.12
	f. Depreciation & amortisation expense	159.27	372.31	135.57	781.52
	g.Other expenses	1,358.54	1109.93	930.28	4458.32
	Total Expenses	3,913.68	3896.84	3650.98	15052.54
5	Profit before exceptional items and tax (3-4)	335.50	109.63	285.26	1091.58
6	Exceptional items	-	-	-	-
7	Profit before tax (5-6)	335.50	109.63	285.26	1091.58
8	Tax expense:				
	Current tax	101.64	98.12	86.88	365.00
	Deferred tax	(34.22)	(66.01)	(16.21)	(59.40)
9	Profit for the period from continuing operations (7-8)	268.08	77.52	214.59	785.98
10	Profit/(loss) from discontinuing operations before Tax	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-
13	Profit for the period (9+12)	268.08	77.52	214.59	785.98



MANUFACTURERS OF PARENTERAL PRODUCTS [CIN: L24230GJ1980PLC003843]



 ADDRESS:
 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA

 TEL.:
 +91 (79) 26925716, 26925719
 FAX:
 +91 (79) 26925710
 Email: denischem401@gmail.com

	Particulars	Quarter ended on			Previous Year ended
		30-06-2023	31-03-2023	30-06-2022	on 31-03-2023
		(Un-audited)	(Audited)	(Un-audited)	(Audited)
14	Other Comprehensive Income				
	Items that will not be reclassified subsequently to profit or loss				
	Gain/(loss) on Remeasurement of defined benefit plan	-	1.59	-	4.63
	Income tax relating to items that will not be reclassified to Profit or loss	-	(0.45)	-	(1.29)
	Items that will be reclassified subsequently to profit or loss	-		-	
	Income tax relating to items that will be reclassified to profit or loss	-		-	
	Other Comprehensive Income, net of tax	-	1.14	-	3.34
15	Total Comprehensive Income for the period (13+14)	268.08	78.66	214.59	789.32
16	Paid-up equity shares capital (Face Value per share Rs.10)	1,387.67	1387.67	1387.67	1387.67
17	Reserves excluding Revaluation Reserves				5838.64
18	Earnings Per Share of Rs.10 each (for continuing operations)				
	- Basic	1.93	0.56	1.55	5.66
	- Diluted	1.93	0.56	1.55	5.66
19	Earnings Per Share of Rs.10 each (for discontinued operations)				
	- Basic			-	-
	- Diluted			-	-
20	Earnings Per Share of Rs10 each (for discontinued & continuing operations)				
	- Basic	1.93	0.56	1.55	5.66
	- Diluted	1.93	0.56	1.55	5.66



MANUFACTURERS OF PARENTERAL PRODUCTS [CIN: L24230GJ1980PLC003843]



 ADDRESS:
 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA

 TEL.:
 +91 (79) 26925716, 26925719
 FAX:
 +91 (79) 26925710
 Email: denischem401@gmail.com

Notes:

1	These Unaudited financial results have been prepared in accordance with the Indian Accounting				
	Standard (referred to as "Ind AS") prescribed under section 133 of the Companies Act, 2013 read with				
	Companies (Indian Accounting Standard) Rules as amended from time to time. These financial results				
	were reviewed by the audit committee and thereafter have been approved by the Board of Directors at its				
	meeting held on Monday, 14 th August, 2023.				
2	The Statutory Auditors have conducted limited review of these results and issued an unmodified opinion				
	on the same.				
3	The Company is operating only in one segment i.e. manufacturing and sales of Transfusion solution in				
	Bottles. Hence there is no any additional disclosure to be made under Ind AS 108 Operating Segments.				
4	The Company does not have any subsidiary/associate.				
5	The Indian Parliament has approved the Code on Social Security, 2020 which would impact the				
	contributions by the Company towards Provident Fund and Gratuity. The Ministry of Labour and				
	Employment has released draft rules for the Code on Social Security, 2020 on 13 th November, 2020 and				
	has invited suggestions from the stakeholders which are under active consideration by the Ministry. The				
	Company will assess the impact and its evaluation once the subject rules are notified and will give				
	appropriate impact in its financial statements in the period in which, the said code become effective				
	including related rules framed thereunder to determine the financial impact are published.				
6	The figures for quarter ended on 31 st March, 2023 are the balancing figures between the audited figures				
	in respect of the full financial year ended on 31 st March, 2023 and the year to date figures up to the third				
	quarter of the financial year 2022-23 which were subjected to limited review by the Statutory Auditors.				
7	Figures, wherever required, are regrouped / rearranged.				
8	The Company has elected to exercise the option permitted u/s 115BAA of the Income- tax Act, 1961 as				
	introduced by the Taxation Laws (Amendment) Ordinance, 2019. The Company has accordingly				
	recognized Provision for Income tax for the quarter ended 30th June,2023. and re-measured its Deferred				
	Tax Assets and Liabilities on the basis of the rate prescribed in the said section. The impact of Rs.11.43				
	lakhs being reduction in deferred tax liability on account of this change has been recognized in the				
	Statement of Profit and Loss for the quarter ended 30th June, 2023.				

For DENIS CHEM LAB LIMITED

Date : 14th August, 2023 Place : Ahmedabad

HIMANSHU C. PATEL MANAGING DIRECTOR (DIN: 00087114)

SHAH & SHAH ASSOCIATES CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the unaudited standalone financial results of M/s. DENIS CHEM LAB LIMITED for the quarter ended on 30th June, 2023 pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

To The Board of Directors of DENIS CHEM LAB LIMITED

- We have reviewed the accompanying statement of unaudited standalone financial results of **DENIS CHEM LAB LIMITED** ("the Company") for the quarter ended 30th June, 2023 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Statement").
- 2. This statement which is the responsibility of the Company's management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting", as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
- 3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410,"Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Attention is drawn to the fact that the figures for the 3 months ended March 31, 2023 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
- 5. Based on our review conducted as stated above nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.



SHAH & SHAH ASSOCIATES CHARTERED ACCOUNTANTS

702, ANIKET, Nr. MUNICIPAL MARKET, C.G. ROAD, NAVRANGPURA, AHMEDABAD – 380 009 PHONE: 26465433 FAX: 079 – 26406983 Email: ca@shahandshah.co.in

6. The review of standalone unaudited financial results for the quarter ended on 30th June,2022 included in the statement was carried out by predecessor auditors who has expressed unmodified conclusion vide their report dated 10th August,2022, whose report has been furnished to us and which have been relied upon by us for the purpose of our review of. Our conclusion is not modified in respect of this matter.



For SHAH & SHAH ASSOCIATES CHARTERED ACCOUNTANTS FRN 113742W

Nc. inn L .

VASANT C. TANNA PARTNER MEMBERSHIP NO.: 100422 ICAI UDIN : 23100422BGSDM56876

DATE: 14TH AUGUST.2023 PLACE: AHMEDABAD